Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;17(2):1106-1112.
doi: 10.3892/etm.2018.6985. Epub 2018 Nov 16.

Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy

Affiliations

Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy

Gabriel Ianosi et al. Exp Ther Med. 2019 Feb.

Abstract

Telangiectasias and reticular veins of the lower extremities are common lesions. Sclerotherapy is considered the gold standard for treatment. The aim of our prospective randomized study was to compare the efficacy and safety of hypertonic 20% saline/2% lignocaine (HS) versus polidocanol 0.5% (POL) versus long-pulsed neodymium:ytrium aluminium garnet (Nd:YAG) laser (LAS) treatments of leg telangiectasias in women, using each patient as her own control. We included in this study 285 women with primary leg telangiectasias and reticular veins (C1AEpAS1PN) in order to be treated with sclerotherapy or laser. One leg was treated with either LAS, POL or HS. The other leg received, randomly, one other of these treatments. At the end there were 190 legs treated with each method. There were two sessions at 8-week interval. Assessment of vessel clearing and complications was conducted 2 months after each session using before and after photographs of the leg vessels using a six-point scale from 0 (no change) to 5 (100% cleared). For telangiectasias under 1 mm diameter LAS was better (RR=9.72, P<0.0001) than HS and also POL was better (RR=2.70, P=0.003); for telangiectasias over 1 mm diameter LAS and POL were better too (RR=2.70, P=0.003) respectively (RR=1.44, P=0.00756). For telangiectasias under 1 mm LAS treatment is clearly superior to POL treatment. For telangiectasias over 1 mm the hazard regression model showed a hazard ratio of 3.97 (P=0.047) for LAS and 4.96 (P=0.486) for POL vs. HS treatment. In conclusion, telangiectasias and reticular veins of the lower extremities can be successfully treated with Nd:YAG laser or sclerotherapy. Nd:YAG laser is recommended in treating small telangiectasias (under 1 mm diameter) while sclerotherapy with polidocanol is more efficient as long as telangiectasias diameter is growing.

Keywords: laser; sclerotherapy; telangiectasias treatment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) The hazard function for the good effect of the 3 treatments in telangiectasias under 1 mm - Diam.1 (B) The hazard function for the good effect of the 3 treatments in telangiectasias over 1 mm - Diam.2 (LAS, laser group; POL, polidocanol group; HS, hypertonic saline group).

Similar articles

Cited by

References

    1. Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29:580–586. doi: 10.1177/0268355513515859. - DOI - PubMed
    1. Tudoraşcu I, Sfredel V, Riza AL, Miulescu Dănciulescu R, Ianoşi SL, Dănoiu S. Motor unit changes in normal aging: A brief review. Rom J Morphol Embryol. 2014;55:1295–1301. - PubMed
    1. Breu FX, Wollmann JC. Clinical and technical follow-up after sclerotherapy. Dermatol Surg. 2010;36(Suppl 2):1004–1009. doi: 10.1111/j.1524-4725.2009.01404.x. - DOI - PubMed
    1. Heck M, Faulhaber J, Breu FX, Schneider SW. Foam sclerotherapy. Uses and indications in dermatology and phlebology. Hautarzt. 2012;63:493–505. (In German) - PubMed
    1. Perrin M, Eklof B, VAN Rij A, Labropoulos N, Vasquez M, Nicolaides A, Blattler W, Bouhassira D, Bouskela E, Carpentier P, et al. Venous symptoms: The SYM Vein Consensus statement developed under the auspices of the European Venous Forum. Int Angiol. 2016;35:374–398. - PubMed